In a study aimed at characterizing the molecular changes in transformed SCLCs, Niederst et al. observed that transformed SCLCs share many features of classical SCLCs, such as universal loss tumor suppression via RB1 and TP53 inactivation, reduced or absent EGFR protein expression, epigenetic changes, and increased sensitivity to BCL-2 inhibition. The gene discussed is EGFR; the disease is neoplasm.